Who are Rigel Pharmaceuticals, Inc.'s main suppliers?

Rigel Pharmaceuticals, Inc. (RIGL) key suppliers include: ARVINAS-ESTROGEN-RECEPTOR-INC, ARVINAS-INC, ARVINAS-OPERATIONS-INC, PFIZER-INC, Curis, Inc. and 4 more. View the full supplier network at chainsifter.com/chain/RIGL.

Who are Rigel Pharmaceuticals, Inc.'s major customers?

Rigel Pharmaceuticals, Inc. (RIGL) key customers include: CENCORA-INC, McKesson Corporation, OPTIME-CARE-INC, Cardinal Health, Inc., Cardinal Health, Inc. and 18 more. View the full customer network at chainsifter.com/chain/RIGL.

What sector is Rigel Pharmaceuticals, Inc. in?

Rigel Pharmaceuticals, Inc. (RIGL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Rigel Pharmaceuticals, Inc. Suppliers, Customers & Supply Chain (RIGL)

9Suppliers

23Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Rigel Pharmaceuticals, Inc. (RIGL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

34Total relationships

4Distinct source URLs

12High confidence

0.757Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Rigel Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ARVINAS-ESTROGEN-RECEPTOR-INC	ARVINAS-ESTROGEN-RECEPTOR-INC	90%	Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
ARVINAS-INC	ARVINAS-INC	90%	Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
ARVINAS-OPERATIONS-INC	ARVINAS-OPERATIONS-INC	90%	Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
PFIZER-INC	PFIZER-INC	85%	In connection with the transition of the Licensed Products, Pfizer will continue to be responsible for certain ongoing development activities, and Rigel has agreed to reimburse the Licensors for cert…
CRIS	Curis, Inc.	72%	Reciprocal relationship from CRIS graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes p…
HCM	HUTCHMED (China) Limited	72%	Reciprocal relationship from HCM graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from HCM graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from HCM grap…
HMDCF	HMDCF	72%	Reciprocal relationship from HMDCF graph: on in China over the coming years. The inclusion was renewed pursuant to which we agreed to a discount of 5% relative to the 2021 NRDL price, and Elunate wil…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing…
ORANY	ORANY	72%	nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement activities and settlements related to their patient suppor…

Rigel Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
CENCORA-INC	CENCORA-INC	90%	Three Months Ended March 31, 2026 2025 Cencora, Inc. 23 % 20 %
MCK	McKesson Corporation	90%	Reciprocal relationship from MCK graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from MCK graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from MCK grap…
OPTIME-CARE-INC	OPTIME-CARE-INC	90%	Three Months Ended March 31, 2026 2025 Optime Care, Inc. ^ — % 11 %
CAH	Cardinal Health, Inc.	85%	ivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the balance sheet. The foll…
CAH	Cardinal Health, Inc.	85%	Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL graph: ivable (as it relates to allowance fo…
MCK	McKesson Corporation	85%	onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of Significant Accounting Policies”, in the “Notes to Financial Statements” contain…
GERN	Geron Corporation	72%	Reciprocal relationship from GERN graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from GERN graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from GERN g…
HCM	HUTCHMED (China) Limited	72%	Reciprocal relationship from HCM graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from HCM graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from HCM grap…
HMDCF	HMDCF	72%	Reciprocal relationship from HMDCF graph: hip with Eli Lilly in China, we are conducting a Phase III study of fruquintinib in third-line non-small cell lung cancer patients, a Phase II study of fruqu…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from LLY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
ORANY	ORANY	72%	nd incident reporting requirements on ‘essential’ and ‘important’ entities, which include ICT managed service providers (MSP), cloud service providers as well as entities carrying out research and de…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORAN…
SNYNF	Sanofi	72%	al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RIGL graph: al sale of any of our product can…
VOR	Vor Biopharma Inc.	72%	Reciprocal relationship from VOR graph: arabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylotarg (gemtuzumab ozogamicin) and Daurismo (glasdegib), Rigel Pharmaceuticals, Inc…
HEALTH-RESOURCES	HEALTH-RESOURCES	62%	FDA can require and could negatively affect prescribing rates, patient willingness to initiate or continue 51 Table of Contents therapy, and payer coverage and reimbursement for GAVRETO. If the box w…
JW-PHARMACEUTICAL-CORPORATION	JW-PHARMACEUTICAL-CORPORATION	62%	s in the revenue derived from the sale of TAVALISSE and thereby materially harm our business and financial condition. TAVALISSE Commercial activities, including sales and marketing Our marketing and …
KISSEI-PHARMACEUTICAL-CO-LTD	KISSEI-PHARMACEUTICAL-CO-LTD	62%	y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
MEDISON-PHARMA-LTD	MEDISON-PHARMA-LTD	62%	y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
MEDISON-PHARMA-TRADING-AG	MEDISON-PHARMA-TRADING-AG	62%	y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
PATHOS-AI-INC	PATHOS-AI-INC	62%	ears of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and…
RAIN-ONCOLOGY-INC	RAIN-ONCOLOGY-INC	62%	ears of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and…

Rigel Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RIGL-DEBT	Debt stack $45.0M	90%	Market cache reports total debt of $45.0M.

Rigel Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
RIGL-OWNER-QUINN-OPPORTUNITY-PARTNERS-LLC	Quinn Opportunity Partners LLC	90%	13F overlay lists Quinn Opportunity Partners LLC as top holder; 13 tracked holders.

Rigel Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CHRS	Coherus Oncology, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
DSGN	Design Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
AMPH	Amphastar Pharmaceuticals, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
HMDCF	HUTCHMED (China) Ltd	100.00	1	['customer', 'supplier']
HCM	HUTCHMED (China) Limited	100.00	1	['customer', 'supplier']
CVS	CVS Health Corporation	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
BPTH	Bio-Path Holdings, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
GERN	Geron Corporation	100.00	1	['customer']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2

Rigel Pharmaceuticals, Inc. Supply Chain